论文部分内容阅读
[目的]探讨非小细胞肺癌(NSCLC)术后标本中ERCC1、TYMS、RRM1、TUBB3表达与化疗疗效的相关性。[方法]回顾性分析我院病理确诊的72例NSCLC患者手术切除的肿瘤标本,通过分支DNA-液相芯片法,检测ERCC1、TYMS、RRM1、TUBB3基因mRNA表达水平。[结果]ERCC1、TYMS、RRM1、TUBB3阳性表达率分别为38.9%(28/72)、62.5%(45/72)、55.6%(46/72)和47.2%(34/72);4者表达与年龄、性别、吸烟、组织学类型、TNM分期、淋巴结转移均无关(P>0.05),TYMS、TUBB3在高、中分化组中的阳性表达率显著低于低分化组(P=0.003,P<0.001)。ERCC1、TYMS、RRM1和TUBB3阳性表达的化疗患者1年生存率均显著低于阴性表达者(61.5%vs95.5%,P=0.048;53.5%vs94.9%,P=0.035;58.6%vs92.9%,P=0.039;47.8%vs97.4%,P=0.014)。[结论]ERCC1、TYMS、RRM1、TUBB3阴性表达者化疗生存率高。ERCC1、TYMS、RRM1、TUBB3阴性表达可作为NSCLC患者临床化疗受益的指标。
[Objective] To investigate the correlation between the expression of ERCC1, TYMS, RRM1 and TUBB3 in non-small cell lung cancer (NSCLC) specimens and the curative effect of chemotherapy. [Methods] Tumor specimens of 72 patients with NSCLC confirmed by pathology in our hospital were retrospectively analyzed. The mRNA expression of ERCC1, TYMS, RRM1 and TUBB3 were detected by branched DNA-liquid phase microarray. [Results] The positive rates of ERCC1, TYMS, RRM1 and TUBB3 were 38.9% (28/72), 62.5% (45/72), 55.6% (46/72) and 47.2% (34/72), respectively The positive rates of TYMS and TUBB3 in high and moderately differentiated group were significantly lower than those in poorly differentiated group (P = 0.003, P <0.05), but not with age, gender, smoking, histological type, TNM stage and lymph node metastasis <0.001). The 1-year survival rates of patients with positive ERCC1, TYMS, RRM1 and TUBB3 expression were significantly lower than those with negative expression (61.5% vs95.5%, P = 0.048; 53.5% vs94.9%, P = 0.035; 58.6% vs92. 9%, P = 0.039; 47.8% vs 97.4%, P = 0.014). [Conclusion] The survival rates of patients with negative expression of ERCC1, TYMS, RRM1 and TUBB3 are high. The negative expression of ERCC1, TYMS, RRM1 and TUBB3 can be used as indicators of the benefit of clinical chemotherapy in patients with NSCLC.